Status:
COMPLETED
Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Erectile Dysfunction
Cardiovascular Diseases
Eligibility:
MALE
18+ years
Brief Summary
Erectile dysfunction (ED) has been identified as an independent risk factor for existing cardiovascular disease, preceding a major cardiovascular event by an average of about 5 years. Are men prescrib...
Eligibility Criteria
Inclusion
- Records of men aged \>18 years with an index PDE5 inhibitor (sildenafil, tadalafil or vardenafil) prescription between January 1st, 1999, and June 30th, 2008
- no prior PDE5 inhibitor prescription before the index prescription
- continuous enrolment with medical history for ≥60 months prior to the index prescription date
Exclusion
- Records of female subjects and any male subjects not meeting the inclusion criteria will be excluded
- A subject can only be selected once independent of the assignment to the target or the control populations.
Key Trial Info
Start Date :
May 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
98832 Patients enrolled
Trial Details
Trial ID
NCT01150903
Start Date
May 1 2010
End Date
August 1 2010
Last Update
July 19 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.